mACE2 expression was detected in 19.6% (21/107) of NSCLC patients, with 10% (11/107) showing a high expression level of IRS2 (10/107) or IRS3 (1/107)) (Figure 2A). The gene discussed is IRS2; the disease is non-small cell lung carcinoma.